Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Isoprinosine in Patients With Lymph Node Disease
NCT00002297 · View on ClinicalTrials.gov ↗
Study Summary
The objectives of this study are to determine the effects of isoprinosine in patients diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will include: Signs and symptoms: * Lymphadenopathy. * Fever. * Weight loss. * Occurrence of opportunistic infections. Cell-mediated immune system parameters: * T-helper cell (OKT4) numbers and proportions. * T-suppressor cell (OKT8) numbers and proportions. * Natural killer (NK) cell activity. * Lymphocyte blastogenic response to phytohemagglutinin (PHA). * Lymphocyte blastogenic response to pokeweed mitogen (PWM). * Immunoglobulin (IgG, IgA, IgM, IgE, IgD) profile. * Circulating immune complexes. Infections characteristically associated with AIDS, such as Candida albicans, Pneumocystis carinii pneumonia, Cytomegalovirus, Herpes simplex, Cryptococcus, Histoplasma, Toxoplasma, Cryptosporidium, Mycobacterium avium- intracellulare, Legionella, and Isospora. Safety parameters: * Blood chemistry including serum uric acid (PurposeA-12). * Complete blood count (CBC). * Platelet count.
Conditions Studied
Interventions
- DRUG Inosine pranobex
Study Locations (1)
California
- Newport Pharmaceuticals International Inc — Laguna Hills
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002297
The ClinicalTrials.gov registry entry for NCT00002297 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Newport Pharmaceuticals International, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention — of which Inosine pranobex is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00002297 reports 1 study location spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00002297 about?
NCT00002297 is a clinical study titled "A Study of Isoprinosine in Patients With Lymph Node Disease". The objectives of this study are to determine the effects of isoprinosine in patients diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will include: Signs and symptoms: * Lymphadenopathy. * Fever. * Weight loss. * Occurrence of opportunistic infections. Cell-m...
What is the current status of trial NCT00002297?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002297 study?
This clinical trial studies the following conditions: HIV Infections, Lymphatic Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00002297?
The interventions under investigation include: Inosine pranobex (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00002297?
This trial is sponsored by Newport Pharmaceuticals International, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00002297 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.